CLINDAMYCIN PALMITATE HYDROCHLORIDE - clindamycin palmitate hydrochloride granule, for solution
Paddock Laboratories, LLC

---------

Clindamycin Palmitate Hydrochloride for Oral Solution, USP

To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin palmitate hydrochloride for oral solution and other antibacterial drugs, clindamycin palmitate hydrochloride for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Not for Injection

WARNING

_Clostridium difficile_ associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of _C. difficile_.

Because clindamycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. _C. difficile_ produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of _C. difficile_ cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against _C. difficile_ may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of _C. difficile_, and surgical evaluation should be instituted as clinically indicated.

DESCRIPTION

Clindamycin palmitate hydrochloride is a water soluble hydrochloride salt of the ester of clindamycin and palmitic acid. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin. The structural formula is represented below:

The chemical name for clindamycin palmitate hydrochloride is Methyl 7-chloro-6, 7, 8- trideoxy-6-(1-
methyl-trans-4-propyl-L-2-pyrrolidin carboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-palmitate monohydrochloride.

Clindamycin palmitate hydrochloride for oral solution flavored granules contain clindamycin palmitate hydrochloride for reconstitution. Each 5 mL contains the equivalent of 75 mg clindamycin. Inactive ingredients: artificial cherry flavor, dextrin, ethylparaben, poloxamer 188, simethicone, sucrose.

**CLINICAL PHARMACOLOGY**

**Human Pharmacology**

**Absorption**

Blood level studies comparing clindamycin palmitate HCI with clindamycin hydrochloride show that both drugs reach their peak active serum levels at the same time, indicating a rapid hydrolysis of the palmitate to the clindamycin.

Serum level studies with clindamycin palmitate HCI in normal pediatric patients weighing 50-100 lbs given 2, 3 or 4 mg/kg every 6 hours (8, 12 or 16 mg/kg/day) demonstrated mean peak clindamycin serum levels of 1.24, 2.25 and 2.44 mcg/mL respectively, one hour after the first dose. By the fifth dose, the 6-hour serum concentration had reached equilibrium. Peak serum concentrations after this time would be about 2.46, 2.98 and 3.79 mcg/mL with doses of 8, 12 and 16 mg/kg/day, respectively. Serum levels have been uniform and predictable from person to person and dose to dose.

**Distribution**

Multiple-dose studies in neonates and infants up to 6 months of age show that the drug does not accumulate in the serum and is excreted rapidly. Serum levels exceed the MICs for most indicated organisms for at least six hours following administration of the usually recommended doses of clindamycin palmitate hydrochloride for oral solution in adults and pediatric patients. Clindamycin is widely distributed in body fluids and tissues (including bones).

No significant levels of clindamycin are attained in the cerebrospinal fluid, even in the presence of inflamed meninges.

**Metabolism**

*In vitro* studies in human liver and intestinal microsomes indicated that clindamycin is predominantly metabolized by Cytochrome P450 3A4 (CYP3A4), with minor contribution from CYP3A5, to form clindamycin sulfoxide and a minor metabolite, N-desmethylclindamycin.

**Excretion**

Approximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as bioinactive metabolites.

The average serum half-life after doses of clindamycin palmitate hydrochloride for oral solution is approximately two hours in pediatric patients.

**Special Populations**

**Renal Impairment**

Serum half-life of clindamycin is increased slightly in patients with markedly reduced renal function. Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum.

**Use in Elderly**

Pharmacokinetic studies in elderly volunteers (61-79 years) and younger adults (18-39 years) indicate that age alone does not alter clindamycin pharmacokinetics (clearance, elimination half-life, volume of distribution, and area under the serum concentration-time curve) after IV administration of clindamycin phosphate. After oral administration of clindamycin hydrochloride, elimination half-life is increased to
approximately 4.0 hours (range 3.4 – 5.1 h) in the elderly compared to 3.2 hours (range 2.1 – 4.2 h) in younger adults; administration of clindamycin palmitate HCl resulted in a similar elimination half-life value of about 4.5 hours in elderly subjects. However, the extent of absorption is not different between age groups and no dosage alteration is necessary for the elderly with normal hepatic function and normal (age-adjusted) renal function.

**Microbiology**

**Mechanism of Action**

Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic.

**Resistance**

Resistance to clindamycin is most often caused by modification of specific bases of the 23S ribosomal RNA. Cross-resistance between clindamycin and lincomycin is complete. Because the binding sites for these antibacterial drugs overlap, cross-resistance is sometimes observed among lincosamides, macrolides and streptogramin B. Macrolide-inducible resistance to clindamycin occurs in some isolates of macrolide-resistant bacteria. Macrolide-resistant isolates of staphylococci and beta-hemolytic streptococci should be screened for induction of clindamycin resistance using the D-zone test.

**Antimicrobial Activity**

Clindamycin has been shown to be active against most of the isolates of the following microorganisms, both in vitro and in clinical infections, as described in the INDICATIONS AND USAGE section.

**Gram-positive Bacteria**

- *Staphylococcus aureus* (methicillin-susceptible strains)
- *Streptococcus pneumoniae* (penicillin-susceptible strains)
- *Streptococcus pyogenes*

**Anaerobic Bacteria**

- *Clostridium perfringens*
- *Fusobacterium necrophorum*
- *Fusobacterium nucleatum*
- *Peptostreptococcus anaerobius*
- *Prevotella melaninogenica*

At least 90% of the microorganisms listed below exhibit in vitro minimum inhibitory concentrations (MICs) less than or equal to the clindamycin susceptible MIC breakpoint for organisms of a similar type to those shown in Table 1. However, the efficacy of clindamycin in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials.

**Gram-positive Bacteria**

- *Staphylococcus epidermidis* (methicillin-susceptible strains)
- *Streptococcus agalactiae*
- *Streptococcus anginosus*
- *Streptococcus mitis*
- *Streptococcus oralis*

**Anaerobic Bacteria**
Susceptibility Testing Methods

When available, the clinical microbiology laboratory should provide cumulative in vitro susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug for treatment.

Dilution Techniques

Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method\(^2,3\) (broth and/or agar). The MIC values should be interpreted according to the criteria provided in Table 1.

Diffusion Techniques

Quantitative methods that require the measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized method\(^2,5\). This procedure uses paper disks impregnated with 2 mcg of clindamycin to test the susceptibility of bacteria to clindamycin. The disk diffusion breakpoints are provided in Table 1.

Anaerobic Techniques

For anaerobic bacteria, the susceptibility to clindamycin can be determined by a standardized test method\(^2,4\). The MIC values obtained should be interpreted according to the criteria provided in Table 1.

Table 1. Susceptibility Test Interpretive Criteria for Clindamycin

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Susceptibility Interpretive Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Minimal Inhibitory Concentrations (MIC in mcg/mL)</td>
</tr>
<tr>
<td>Staphylococcus spp.</td>
<td>S ≤ 0.5  I 1-2  R ≥ 4</td>
</tr>
<tr>
<td>Streptococcus pneumoniae and other Streptococcus spp.</td>
<td>≤ 0.25  0.5  ≥ 1</td>
</tr>
<tr>
<td>Anaerobic Bacteria</td>
<td>≤ 2  4  ≥ 8</td>
</tr>
</tbody>
</table>

NA=not applicable
A report of **Susceptible (S)** indicates that the antimicrobial drug is likely to inhibit growth of the pathogen if the antimicrobial drug reaches the concentration usually achievable at the site of infection. A report of **Intermediate (I)** indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small, uncontrolled technical factors from causing major discrepancies in interpretation.

A report of **Resistant (R)** indicates that the antimicrobial drug is not likely to inhibit growth of the pathogen if the antimicrobial drug reaches the concentration usually achievable at the site of infection; other therapy should be selected.

**Quality Control**

Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test. Standard clindamycin powder should provide the MIC ranges in Table 2. For the disk diffusion technique using the 2 mcg clindamycin disk the criteria provided in Table 2 should be achieved.

**Table 2. Acceptable Quality Control Ranges for Clindamycin**

<table>
<thead>
<tr>
<th>QC Strain</th>
<th>Acceptable Quality Control Ranges</th>
<th>Disk Diffusion Range (Zone Diameters in mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Minimum Inhibitory Concentration Range (mcg/mL)</td>
<td></td>
</tr>
<tr>
<td><strong>Enterococcus faecalis</strong>&lt;sup&gt;1&lt;/sup&gt; ATCC 29212</td>
<td>4-16</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Staphylococcus aureus</strong> ATCC 29213</td>
<td>0.06-0.25</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Staphylococcus aureus</strong> ATCC 25923</td>
<td>NA</td>
<td>24-30</td>
</tr>
<tr>
<td><strong>Streptococcus pneumoniae</strong> ATCC 49619</td>
<td>0.03-0.12</td>
<td>19-25</td>
</tr>
<tr>
<td><strong>Bacteroides fragilis</strong> ATCC 25285</td>
<td>0.5-2</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Bacteroides thetaiotaomicron</strong> ATCC 29741</td>
<td>2-8</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Clostridium difficile</strong>&lt;sup&gt;2&lt;/sup&gt; ATCC 700057</td>
<td>2-8</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Eggerthella lenta</strong> ATCC 43055</td>
<td>0.06-0.25</td>
<td>NA</td>
</tr>
</tbody>
</table>

1. **Enterococcus faecalis** has been included in this table for quality control purposes only.

2. Quality control for **C. difficile** is performed using the agar dilution method only, all other obligate anaerobes may be tested by either broth microdilution or agar dilution methods.

NA=Not applicable

ATCC® is a registered trademark of the American Type Culture Collection
INDICATIONS AND USAGE

Clindamycin palmitate hydrochloride for oral solution is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).

Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection.

Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections.

Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections.

Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin palmitate hydrochloride for oral solution and other antibacterial drugs, clindamycin palmitate hydrochloride for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

CONTRAINDICATIONS

This drug is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

WARNINGS

See BOXED WARNING.

Clostridium difficile Associated Diarrhea

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin palmitate hydrochloride, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Anaphylactic and Severe Hypersensitivity Reactions
Anaphylactic shock and anaphylactic reactions have been reported (see ADVERSE REACTIONS).

Severe hypersensitivity reactions, including severe skin reactions such as toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and Stevens-Johnson syndrome (SJS), some with fatal outcome, have been reported (see ADVERSE REACTIONS).

In case of such an anaphylactic or severe hypersensitivity reaction, discontinue treatment permanently and institute appropriate therapy.

A careful inquiry should be made concerning previous sensitivities to drugs and other allergens.

**Usage in Meningitis:** Since clindamycin does not diffuse adequately into the cerebrospinal fluid, the drug should not be used in the treatment of meningitis.

**PRECAUTIONS**

**General**

Review of experience to date suggests that a subgroup of older patients with associated severe illness may tolerate diarrhea less well. When clindamycin is indicated in these patients, they should be carefully monitored for change in bowel frequency. Clindamycin palmitate hydrochloride for oral solution should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. Clindamycin palmitate hydrochloride for oral solution should be prescribed with caution in atopic individuals.

Indicated surgical procedures should be performed in conjunction with antibiotic therapy. The use of clindamycin palmitate hydrochloride for oral solution occasionally results in overgrowth of nonsusceptible organisms—particularly yeasts. Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.

Clindamycin dosage modification may not be necessary in patients with renal disease. In patients with moderate to severe liver disease, prolongation of clindamycin half-life has been found. However, it was postulated from studies that when given every eight hours, accumulation should rarely occur. Therefore, dosage modification in patients with liver disease may not be necessary. However, periodic liver enzyme determinations should be made when treating patients with severe liver disease.

Prescribing clindamycin palmitate hydrochloride for oral solution in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

**Information for Patients**

Patients should be counseled that antibacterial drugs including clindamycin palmitate hydrochloride for oral solution should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When clindamycin palmitate hydrochloride for oral solution is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by clindamycin palmitate hydrochloride for oral solution or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

**Laboratory Tests**

During prolonged therapy, periodic liver and kidney function tests and blood counts should be
Drug Interactions

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.

Clindamycin is metabolized predominantly by CYP3A4, and to a lesser extent by CYP3A5, to the major metabolite clindamycin sulfoxide and minor metabolite N-desmethylclindamycin. Therefore inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin. In the presence of strong CYP3A4 inhibitors, monitor for adverse reactions. In the presence of strong CYP3A4 inducers such as rifampicin, monitor for loss of effectiveness.

In vitro studies indicate that clindamycin does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2E1 or CYP2D6 and only moderately inhibits CYP3A4.

Antagonism has been demonstrated between clindamycin and erythromycin in vitro. Because of possible clinical significance, these two drugs should not be administered concurrently.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential. Genotoxicity tests performed included a rat micronucleus test and an Ames Salmonella reversion test. Both tests were negative.

Fertility studies in rats treated orally with up to 300 mg/kg/day (approximately 1.6 times the highest recommended adult human oral dose based on mg/m²) revealed no effects on fertility or mating ability.

Pregnancy: Teratogenic Effects

In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of congenital abnormalities.

Clindamycin should be used during the first trimester of pregnancy only if clearly needed. There are no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy. Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed.

Reproduction studies performed in rats and mice using oral doses of clindamycin up to 600 mg/kg/day (3.2 and 1.6 times the highest recommended adult human dose based on mg/m², respectively) or subcutaneous doses of clindamycin up to 250 mg/kg/day (1.3 and 0.7 times the highest recommended adult human dose based on mg/m², respectively) revealed no evidence of teratogenicity.

Nursing Mothers

Clindamycin has been reported to appear in breast milk in the range of 0.7 to 3.8 mcg/mL. Clindamycin has the potential to cause adverse effects on the breastfed infant's gastrointestinal flora. If oral or intravenous clindamycin is required by a nursing mother, it is not a reason to discontinue breastfeeding, but an alternate drug may be preferred. Monitor the infant for possible adverse effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clindamycin and any potential adverse effects on the breastfed child from clindamycin or from the underlying maternal condition.

Pediatric Use
When clindamycin palmitate hydrochloride for oral solution is administered to the pediatric population (birth to 16 years), appropriate monitoring of organ system functions is desirable.

**Geriatric Use**

Clinical studies of clindamycin did not include sufficient numbers of patients age 65 and over to determine whether they respond differently from younger patients. However, other reported clinical experience indicates that antibiotic-associated colitis and diarrhea (due to *Clostridium difficile*) seen in association with most antibiotics occur more frequently in the elderly (>60 years) and may be more severe. These patients should be carefully monitored for the development of diarrhea.

Pharmacokinetic studies with clindamycin have shown no clinically important differences between young subjects (18-39 years) and elderly subjects (61-79 years) with normal hepatic function and normal (age-adjusted) renal function after oral or intravenous administration.

**ADVERSE REACTIONS**

The following reactions have been reported with the use of clindamycin.

*Infections and infestations: Clostridium difficile* colitis

*Gastrointestinal:* Abdominal pain, pseudomembranous colitis, esophagitis, nausea, vomiting and diarrhea (see **BOXED WARNING**). The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment (see **WARNINGS**). An unpleasant or metallic taste has been reported after oral administration.

*Hypersensitivity Reactions:* Generalized mild to moderate morbilliform-like (maculopapular) skin rashes are the most frequently reported adverse reactions. Vesiculobullous rashes, as well as urticaria, have been observed during drug therapy. Severe skin reactions such as Toxic Epidermal Necrolysis, some with fatal outcome, have been reported (See **WARNINGS**). Cases of Acute Generalized Exanthematous Pustulosis (AGEP), erythema multiforme, some resembling Stevens-Johnson syndrome, anaphylactic shock, anaphylactic reaction and hypersensitivity have also been reported.

*Skin and Mucous Membranes:* Pruritus, vaginitis, angioedema, and rare instances of exfoliative dermatitis have been reported. (See **Hypersensitivity Reactions**.)

*Liver:* Jaundice and abnormalities in liver function tests have been observed during clindamycin therapy.

*Renal:* Although no direct relationship of clindamycin to renal damage has been established, renal dysfunction as evidenced by azotemia, oliguria, and/or proteinuria has been observed.

*Hematopoietic:* Transient neutropenia (leukopenia) and eosinophilia have been reported. Reports of agranulocytosis and thrombocytopenia have been made. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of the foregoing.

*Immune system:* Drug reaction with eosinophilia and systemic symptoms (DRESS) cases have been reported.

*Musculoskeletal:* Cases of polyarthritis have been reported.

**OVERDOSAGE**

Significant mortality was observed in mice at an intravenous dose of 855 mg/kg and in rats at an oral or subcutaneous dose of approximately 2618 mg/kg. In the mice, convulsions and depression were observed. Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum.

**DOSAGE AND ADMINISTRATION**
If significant diarrhea occurs during therapy, this antibiotic should be discontinued (see **BOXED WARNING**).

Concomitant administration of food does not adversely affect the absorption of clindamycin palmitate HCl contained in clindamycin palmitate hydrochloride Flavored Granules.

Serious infections: 8-12 mg/kg/day (4-6 mg/lb/day) divided into 3 or 4 equal doses.
Severe infections: 13-16 mg/kg/day (6.5-8 mg/lb/day) divided into 3 or 4 equal doses.
More severe infections: 17-25 mg/kg/day (8.5-12.5 mg/lb/day) divided into 3 or 4 equal doses.

In pediatric patients weighing 10 kg or less, ½ teaspoon (37.5 mg) three times a day should be considered the minimum recommended dose.

Serious infections due to anaerobic bacteria are usually treated with Clindamycin Injection, USP. However, in clinically appropriate circumstances, the physician may elect to initiate treatment or continue treatment with clindamycin palmitate hydrochloride for oral solution.

**NOTE:** In cases of ß-hemolytic streptococcal infections, treatment should be continued for at least 10 days.

**Reconstitution Instructions:** When reconstituted with water as follows, each 5 mL (teaspoon) of solution contains clindamycin palmitate HCl equivalent to 75 mg clindamycin.

Reconstitute bottles of 100 mL with 75 mL of water. Add a large portion of the water and shake vigorously; add the remainder of the water and shake until the solution is uniform.

**Storage Conditions:**
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]

Do **NOT** refrigerate the reconstituted solution; when chilled, the solution may thicken and be difficult to pour. The solution is stable for 2 weeks at room temperature.

**HOW SUPPLIED**
Clindamycin Palmitate Hydrochloride for Oral Solution, USP is available in bottles of 100 mL (NDC 0574-0129-01).

When reconstituted as directed, each bottle yields a solution containing 75 mg of clindamycin per 5 mL.

**Rx only**

**References**

Manufactured by
PRINCIPAL DISPLAY PANEL - Carton

Rx Only
NDC 0574-0129-01
Clindamycin Palmitate Hydrochloride for Oral Solution, USP 75 mg
When reconstituted each 5 mL contains
Cherry Flavored
100 mL
(when mixed)
Clindamycin Palmitate Hydrochloride for Oral Solution, USP

75 mg

When reconstituted each 5 mL contains

WARNING: NOT FOR INJECTION
DO NOT REFRIGERATE SOLUTION

Cherry Flavored

100 mL (when mixed)

---

**CLINDAMYCIN PALMITATE HYDROCHLORIDE**

clindamycin palmitate hydrochloride granule, for solution

### Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
<th>NDC: 0574-0129</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORAL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLINDAMYCIN PALMITATE HYDROCHLORIDE (UNII: VN9A8JM7M7) (Clindamycin - UNII:3U02EL437C)</td>
<td>Clindamycin</td>
<td>75 mg in 5 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETHYL.PARABEN (UNII: 14255EXE39)</td>
<td></td>
</tr>
<tr>
<td>POLYOXAMER 188 (UNII: LQA7B6G8JG)</td>
<td></td>
</tr>
<tr>
<td>SUCROSE (UNII: C151H8M554)</td>
<td></td>
</tr>
</tbody>
</table>
SUCROSE (UNII: C151H8M554)
ICODEXTRIN (UNII: 2NX48Z0A9G)
DIMETHICONE (UNII: 92RU3N3Y1O)
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)

Product Characteristics

<table>
<thead>
<tr>
<th>Color</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shape</td>
<td>Size</td>
</tr>
<tr>
<td>Flavor</td>
<td>Imprint Code</td>
</tr>
<tr>
<td>Contains</td>
<td></td>
</tr>
</tbody>
</table>

Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0574-0129-01</td>
<td>1 in 1 CARTON</td>
<td>01/21/2010</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>100 mL in 1 BOTTLE, GLASS; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA090902</td>
<td>01/21/2010</td>
<td></td>
</tr>
</tbody>
</table>

Labeler - Paddock Laboratories, LLC (967694121)

Registrant - L. Perrigo Company (006013346)

Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paddock Laboratories, LLC</td>
<td></td>
<td>967694121</td>
<td>MANUFACTURE(0574-0129)</td>
</tr>
</tbody>
</table>

Revised: 9/2017